. Author manuscript; available in PMC: 2010 May 24.

Published in final edited form as: Clin Cancer Res. 2009 Mar 10;15(6):2091–2097. doi: 10.1158/1078-0432.CCR-08-2036

Table 2. FISH results for androgen receptor (AR)^, MYC*^**, and MYC/8p^*** results.

	AR FISH results

	Amplification	Copy Gain	NAD	Total
No. of patients (%)	17 (34.7%)	13 (26.5%)	19 (38.8%)	49
Median CTC counts (1^st–3rd quartiles)	90 (39–114)	26 (12–86)	4 (3–10)	26.5 (5–99.5)

CTC <10 (%)	0	3 (20%)	12 (80%)	15
CTC ≥10 (%)	17 (50%)	10 (29.4%)	7 (20.6%)	34

	MYC FISH results

No. of patients (%)	1 (1.9%)	32 (59.3%)	21 (38.9%)	54
Median CTC counts (1^st–3^rd quartiles)	11	53 (24–101)	5.5 (2–39)	27 (6–86.5)

CTC <10 (%)	0	4 (25%)	12 (75%)	16
CTC ≥10 (%)	1 (2.6%)	28 (73.7%)	9 (23.7%)	38

	Gain MYC, 8p ratio >=1.5	Gain MYC, 8p ratio 1	NAD	Total

No. of patients (%)	24 (55.8%)	5 (11.6%)	14 (32.6%)	43
Median CTC counts (1^st–3^rd quartiles)	72 (32.3–107.3)	55 (12–86)	10 (2–27)	24 (11–90)

CTC <10 (%)	0	1 (12.5%)	7 (87.5%)	8
CTC ≥10 (%)	24 (68.6%)	4 (11.4%)	7 (20%)	35

No result was obtained from 5 samples, median CTC number 56 (IQR 28–271).

^**

Abnormalities were seen in 33 of 54 patients successfully analyzed. No result was obtained from 10 samples, median CTC number 46.5 (IQR 24–294).

^***

No result was obtained from 6 samples, median CTC number 24 (IQR 9–135). NAD = no abnormality detected.

Table 2. FISH results for androgen receptor (AR)*, MYC**, and MYC/8p*** results.